Cameron Turtle
CIK 1758363 · Chief Executive Officer · last filed 2026-09-03
Cameron Turtle is a Chief Executive Officer who has filed 50 SEC Form 4 insider transactions across 6 companies since 2019. The most recent filing shows the insider sold $1.3M of SYRE on Sep 3, 2026. Across all open-market trades the lifetime net is −$21.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $53.5M across reported positions. 16 SEC filings were submitted jointly with BridgeBio Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$53.52M
6
50
-$21.84M
Filer Profile
221 CRESCENT STREET, SUITE 105
WALTHAM, MA 02453
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYRE | Chief Executive Officer | 565,040 | $90.60 | $51.19M | -$9.99M | 15 | 2026-09-03 |
| DMRA | Director | — | $28.10 | — | $0 | 1 | 2026-03-25 |
| ORKA | Director | — | $92.38 | — | $0 | 1 | 2025-06-03 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Chief Executive Officer | 746,507 | $12.01 | $8.97M | $0 | 1 | 2023-11-27 |
| BBIO | See Remarks | 32,068 | $72.44 | $2.32M | -$3.63M | 15 | 2020-12-29 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | Chief Business Officer | 73,159 | — | — | -$8.21M | 13 | 2020-12-16 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-03 | SYRE | Sell (S) | −15,000 | -$1.31M | EDGAR |
| 2026-08-05 | SYRE | Sell (S) | −15,000 | -$1.43M | EDGAR |
| 2026-07-02 | SYRE | Sell (S) | −15,000 | -$1.32M | EDGAR |
| 2026-07-01 | SYRE | Notice (144) | −45,000 | -$4.00M | EDGAR |
| 2026-06-03 | SYRE | Sell (S) | −15,000 | -$1.06M | EDGAR |
| 2026-05-01 | SYRE | Sell (S) | −15,000 | -$1.07M | EDGAR |
| 2026-04-03 | SYRE | Sell (S) | −15,000 | -$739.9K | EDGAR |
| 2026-03-25 | DMRA | Grant (A) | — | $0 | EDGAR |
| 2026-03-03 | SYRE | Sell (S) | −15,000 | -$632.9K | EDGAR |
| 2026-03-02 | SYRE | Notice (144) | −60,000 | -$2.58M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.